UK Stocks-Factors to watch on May 27 (updated)
UPDATE 1-UK Stocks-Factors to watch on May 27 Adds news items, updates futures
May 27 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Wednesday, with futures FFIc1 down 0.10%.
* ASTRAZENECA: AstraZeneca AZN.L said the U.S. Food and Drug Administration has extended its review deadline for its experimental breast cancer pill camizestrant to assess additional data.
* PETS AT HOME: Pets at Home PETSP.L reported a 30.2% drop in annual underlying pretax profit in line with market expectations, as weaker retail earnings and price cuts offset continued growth in its veterinary business.
* ENERGY PRICE CAP: British energy regulator Ofgem said it would raise the energy price cap by 13% from July to September, adding about £18 ($24.20) to monthly bills for households using both electricity and gas, as energy prices surge due to the Iran war.
* OIL: Oil prices pulled back from recent highs, erasing some of the previous day's 4% gain as traders sought clarity on complex negotiations between Iran and the U.S. after renewed hostilities set back efforts to reopen the Strait of Hormuz.
* METALS: London copper prices rose to a near two-week high as lower oil prices eased fears of inflation and slowing economic growth.
* GOLD: Gold prices edged lower as investors assessed ongoing tensions between the U.S. and Iran, and awaited comments from Federal Reserve officials for monetary policy clues.
* For more on the factors affecting European stocks, please click on: LIVE/
TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB
(Compiled by Neeshita Beura and Roshni Srivastava in Bengaluru; Editing by Nivedita Bhattacharjee)
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains